
|Videos|June 5, 2023
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Advertisement
Episodes in this series
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Advertisement
Related to this article

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

The top 5 OncLive TV videos of the week cover insights in NSCLC, HER2+ gastroesophageal cancer, low-grade glioma, HR+ breast cancer, and CML.

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
The OncFive: Top Oncology Articles for the Week of 11/15
3
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
4
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
5




